These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 4802235)

  • 1. [Hemodynamic response to prolonged treatment with L-dopa in cirrhotic patients].
    Cagossi M; Bianco A; Butti A; Ghirlanda G; Suraci V; Fianchini A; Borzone A; Lojacono L; Nanni G; Cagossi M
    Chir Patol Sper; 1973 Dec; 21(5-6):349-72. PubMed ID: 4802235
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemodynamic response to the acute treatment with levodopa in cirrhotic patients].
    Butti A; Borzone A; Nanni G; Cagossi M; Civello IM; Bianco A; Lojacono L
    Chir Patol Sper; 1975 Jun; 23(3):123-38. PubMed ID: 1222622
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hemodynamic, psychometric and EEG evaluation of L-DOPA treatment in patients affected by hepatocirrhosis (author's transl)].
    Bergonzi P; Bianco A; Cagossi M; Cagossi M; Mennuni G
    Riv Patol Nerv Ment; 1974 Oct; 95(5):685-93. PubMed ID: 4470269
    [No Abstract]   [Full Text] [Related]  

  • 4. [Preliminary study on the hemodynamics of cirrhotic patients treated with L-dopa].
    Cagossi M; Bianco S; Butti A; Lojacono L
    Chir Patol Sper; 1973 Apr; 21(2):148-61. PubMed ID: 4785867
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.
    Michel H; Solere M; Granier P; Cauvet G; Bali JP; Pons F; Bellet-Hermann H
    Gastroenterology; 1980 Aug; 79(2):207-11. PubMed ID: 6995221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Broussolle E
    Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
    [No Abstract]   [Full Text] [Related]  

  • 11. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary factors in the management of Parkinson's disease.
    Kempster PA; Wahlqvist ML
    Nutr Rev; 1994 Feb; 52(2 Pt 1):51-8. PubMed ID: 8183469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
    Defer GL
    Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal systemic hemodynamic stability for successful clinical outcomes after adult living-donor liver transplantation: prospective observational study.
    Hori T; Yagi S; Iida T; Taniguchi K; Yamagiwa K; Yamamoto C; Hasegawa T; Yamakado K; Kato T; Saito K; Wang L; Torii M; Hori Y; Takeda K; Maruyama K; Uemoto S
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e170-8. PubMed ID: 18422962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa response in Parkinsonism with multiple mitochondrial DNA deletions.
    Wilcox RA; Churchyard A; Dahl HH; Hutchison WM; Kirby DM; Thyagarajan D
    Mov Disord; 2007 May; 22(7):1020-3. PubMed ID: 17357142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disturbed intracortical excitability in early Parkinson's disease is l-DOPA dose related: a prospective 12-month paired TMS study.
    Bares M; Kanovský P; Rektor I
    Parkinsonism Relat Disord; 2007 Dec; 13(8):489-94. PubMed ID: 17449315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of erythropoietin or nitric oxide synthesis inhibitor on hyperdynamic circulatory state in cirrhotic rats].
    Huang Y; Xiao S; Zhang D
    Zhonghua Yi Xue Za Zhi; 1998 Feb; 78(2):139-42. PubMed ID: 10923428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemodynamics in liver cirrhosis. Hemodynamic peculiarities and possibility of their modification by vasoactive agents in patients with liver cirrhosis].
    Baltzer G
    Fortschr Med; 1973 Feb; 91(6):253-7. PubMed ID: 4806240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.